Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

199 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Monoclonal antibody therapy for breast cancer: herceptin.
Finn RS, Slamon DJ. Finn RS, et al. Cancer Chemother Biol Response Modif. 2003;21:223-33. doi: 10.1016/s0921-4410(03)21010-3. Cancer Chemother Biol Response Modif. 2003. PMID: 15338747 Review. No abstract available.
Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.
Jani JP, Finn RS, Campbell M, Coleman KG, Connell RD, Currier N, Emerson EO, Floyd E, Harriman S, Kath JC, Morris J, Moyer JD, Pustilnik LR, Rafidi K, Ralston S, Rossi AM, Steyn SJ, Wagner L, Winter SM, Bhattacharya SK. Jani JP, et al. Among authors: finn rs. Cancer Res. 2007 Oct 15;67(20):9887-93. doi: 10.1158/0008-5472.CAN-06-3559. Cancer Res. 2007. PMID: 17942920
A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
Camidge DR, Gail Eckhardt S, Gore L, O'Bryant CL, Leong S, Basche M, Holden SN, Musib L, Baldwin J, Darstein C, Thornton D, Finn RS, Britten CD. Camidge DR, et al. Among authors: finn rs. Anticancer Drugs. 2008 Jan;19(1):77-84. doi: 10.1097/CAD.0b013e3282f077b3. Anticancer Drugs. 2008. PMID: 18043132 Clinical Trial.
Targeting Src in breast cancer.
Finn RS. Finn RS. Ann Oncol. 2008 Aug;19(8):1379-1386. doi: 10.1093/annonc/mdn291. Epub 2008 May 16. Ann Oncol. 2008. PMID: 18487549 Review.
199 results